Table 1.
Neutralization antibody titer and onset of death following FIPV challenge
Group | Vaccine | Cat no. | Days post-challenge |
Day of death | ||||||||||
0 | 12 | 18 | 19 | 23 | 26 | 29 | 31 | 44 | 48 | 60 | ||||
First exp. | Recombinant N protein | Y-1 | <10 | 20 | 80 | 6400 | Survival | |||||||
Y-2 | <10 | 160 | 320 | 6400 | Survival | |||||||||
Y-3 | <10 | 40 | 160 | 6400 | 48 | |||||||||
Y-4 | <10 | 40 | 80 | 1600 | Survival | |||||||||
Controls (SF-9 cells) | Y-5 | <10 | 80 | 320 | 6400 | 44 | ||||||||
Y-6 | <10 | 80 | 160 | 1600 | 31 | |||||||||
Y-7 | <10 | 80 | 160 | 800 | 23 | |||||||||
Y-8 | <10 | 80 | 160 | 1600 | 26 | |||||||||
Second exp. | Recombinant N protein | O-1 | <10 | 40 | 200 | 19 | ||||||||
O-2 | <10 | 20 | 80 | 6400 | Survival | |||||||||
O-3 | <10 | 20 | 80 | 3200 | Survival | |||||||||
O-4 | <10 | 10 | 40 | 3200 | Survival | |||||||||
Controls (SF-9 cells) | O-5 | <10 | 10 | 40 | 400 | 29 | ||||||||
O-6 | <10 | 40 | 160 | 3200 | 60 | |||||||||
O-7 | <10 | 40 | 160 | 6400 | Survival | |||||||||
O-8 | <10 | 40 | 80 | 200 | 23 |